NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results?Zacks Investment Research • 10/28/26
Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder CancerBusiness Wire • 10/27/26
Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™Business Wire • 10/26/26
Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree.The Motley Fool • 10/26/26
Natera Partners With TransCode to Advance Colorectal Cancer TrialZacks Investment Research • 10/21/26
ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD TechnologyBusiness Wire • 10/18/26
Natera's Signatera™ MRD Test Named to TIME's List of the Best Inventions of 2026Business Wire • 10/15/26
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal CancerBusiness Wire • 10/13/26
FDA Grants Breakthrough Device Designation for Natera's Multi-Cancer Early Detection AssayBusiness Wire • 10/09/26
Natera Announces Randomized, Signatera™-Guided Interventional Study in MelanomaBusiness Wire • 10/07/26
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation OncologistsBusiness Wire • 10/06/26
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech's Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast CancerBusiness Wire • 10/05/26
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDxZacks Investment Research • 09/23/26
Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder CancerBusiness Wire • 09/22/26